{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T23:37:05Z","timestamp":1773617825175,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin\u201017A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long\u2010term efficacy and safety of secukinumab for 52 weeks in real\u2010world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio\u2010switched patients. Psoriasis Area and Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) 75 and <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>\u201090 responses were 80% and 64% at week 12, 77% and 65% at week 24, and 76% and 58% at week 52, respectively. No significant differences were observed in efficacy between bio\u2010naive and bio\u2010switched patients. Arthralgia showed improvement by week 12 in all patients with psoriatic arthritis with a reduction of serum C\u2010reactive protein level. Treatment was discontinued in 22% (18\/83), including eight patients with no improvement or exacerbation of cutaneous manifestations, one patient with new onset of arthritis and two patients with transient infection. Overall, secukinumab showed a sustained clinical response with an acceptable safety profile through week 52 in Japanese psoriatic patients.<\/jats:p>","DOI":"10.1111\/1346-8138.14145","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T12:23:20Z","timestamp":1512044600000},"page":"318-321","source":"Crossref","is-referenced-by-count":26,"title":["Long\u2010term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single\u2010center experience"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-1223","authenticated-orcid":false,"given":"Mami","family":"Momose","sequence":"first","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Umezawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidemi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology The Jikei University School of Medicine Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12070"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13814"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12668"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14965"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13911"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.183"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.14145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.14145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T04:01:51Z","timestamp":1694491311000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.14145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/1346-8138.14145"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.14145","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]}}}